At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
- A Phase 2 Study Assessing Treatment for Inflammation Before a Stem Cell Transplant in People with Immune and Autoinflammatory Conditions
Full Title Phase 2 Study Bridging Pre-Transplant Inflammatory Dampening for Primary Immune Regulatory Disorders (BRIDGE Trial)
Purpose
Primary immune regulatory disorder (PIRD) and autoinflammatory conditions are conditions of the immune system that can cause an unusual amount of inflammation. While a stem cell transplant is a standard treatment for people with a PIRD or autoinflammatory condition, the inflammation caused by these conditions can reduce the effectiveness of this treatment.
In this study, researchers are assessing treatment before transplant with emapalumab or fludarabine/dexamethasone in people with a PIRD and/or an autoinflammatory condition who are planning to have a stem cell transplant. Emapalumab or fludarabine/dexamethasone are drugs that may help reduce inflammation and enable people with a PIRD and/or an autoinflammatory condition to have a successful stem cell transplant. These drugs work by either directly blocking proteins that cause inflammation or inactivating immune cells that promote inflammation.
The medications used in this study are given intravenously (by vein). Participants will receive one of two study treatments before their stem cell transplant:
- Emapalumab
- Fludarabine and dexamethasone
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have a PIRD and/or an autoinflammatory condition and be planning to have a stem cell transplant.
- Patients must have an appropriate stem cell donor.
- This study is for people of all ages.
Contact
For more information and to ask about eligibility for this study, please contact the office of Dr. Joseph Oved at 646-888-3314.
Protocol
23-040Phase
Phase II (phase 2)Disease Status
Newly DiagnosedInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05787574ClinicalTrials.gov
-
Rilvegostomig may help your immune system fight your cancer. It sticks to and blocks signaling from two molecules called PD-1 and TIGIT on immune cells. Cancer cells use PD-1 and TIGIT to avoid being attacked by the immune system so they can grow and survive. By stopping cancer cells from using these molecules, rilvegostomig may help your immune system find and attack cancer cells.
-
Researchers are comparing two combination treatments for breast cancer that has metastasized (spread) or is inoperable (cannot be removed surgically). The people in this study have breast cancer that has hormone receptors (HR) but is negative for the HER2 protein.
-
Researchers want to find the best dose of ETX-19477 to treat cancer. The people in this study have solid tumors that keep growing even after treatment.
-
The purpose of this study is to find the highest dose of the investigational drug NVL-520 that can be given safely in people with metastatic solid tumors that contain a change (fusion) involving the ROS1 gene. A fusion gene is made when parts of two different genes join together. NVL-520 blocks the ROS1 protein, which promotes cancer cell growth and survival. It is taken orally (by mouth
-
This study is assessing axicabtagene clioleucel CAR T cell therapy for people with HIV-related aggressive B cell lymphoma. The people in this study have B cell non-Hodgkin lymphoma that has come back or keeps growing after treatment, including:
-
Researchers are assessing the use of multiple medications given before surgery to treat esophagogastric cancers. The people in this study have esophagus, stomach, or gastro-esophageal junction cancers that can be taken out (operable). In addition, their cancers make a protein called HER2.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers want to see if a lower dose of radiation therapy works as well as the standard dose in people with lymphoma. The people in this study have B-cell lymphoma that has not yet been treated.
-
Researchers want to see how well a new cellular immunotherapy works to treat multiple myeloma. The people in this study have multiple myeloma that keeps growing or came back after treatment.